| General Information | |
|---|---|
| ZINC ID | ZINC000027755607 |
| Molecular Weight (Da) | 348 |
| SMILES | C#CCCCC#CCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)C[C@H]21 |
| Molecular Formula | C24O2 |
| Action | Partial Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 99.337 |
| HBA | 2 |
| HBD | 2 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 26 |
| LogP | 7.316 |
| Activity (Ki) in nM | 4.6774 |
| Polar Surface Area (PSA) | 29.46 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.998 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 6 |
| Fraction csp3 | 0.5 |
| Ilogp | 4.45 |
| Xlogp3 | 7.06 |
| Wlogp | 5.51 |
| Mlogp | 4.87 |
| Silicos-it log p | 6.11 |
| Consensus log p | 5.6 |
| Esol log s | -6.42 |
| Esol solubility (mg/ml) | 0.000132 |
| Esol solubility (mol/l) | 0.00000037 |
| Esol class | Poorly sol |
| Ali log s | -7.5 |
| Ali solubility (mg/ml) | 0.0000111 |
| Ali solubility (mol/l) | 3.19E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -5.69 |
| Silicos-it solubility (mg/ml) | 0.000715 |
| Silicos-it solubility (mol/l) | 0.00000205 |
| Silicos-it class | Moderately soluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.41 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 2 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 4.51 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.603 |
| Logd | 4.847 |
| Logp | 6.781 |
| F (20%) | 0.996 |
| F (30%) | 0.978 |
| Mdck | - |
| Ppb | 96.46% |
| Vdss | 4.321 |
| Fu | 0.48% |
| Cyp1a2-inh | 0.611 |
| Cyp1a2-sub | 0.775 |
| Cyp2c19-inh | 0.958 |
| Cyp2c19-sub | 0.622 |
| Cl | 4.84 |
| T12 | 0.118 |
| H-ht | 0.964 |
| Dili | 0.177 |
| Roa | 0.167 |
| Fdamdd | 0.952 |
| Skinsen | 0.697 |
| Ec | 0.004 |
| Ei | 0.066 |
| Respiratory | 0.877 |
| Bcf | 2.832 |
| Igc50 | 4.863 |
| Lc50 | 5.61 |
| Lc50dm | 6.349 |
| Nr-ar | 0.032 |
| Nr-ar-lbd | 0.026 |
| Nr-ahr | 0.592 |
| Nr-aromatase | 0.526 |
| Nr-er | 0.341 |
| Nr-er-lbd | 0.588 |
| Nr-ppar-gamma | 0.866 |
| Sr-are | 0.892 |
| Sr-atad5 | 0.017 |
| Sr-hse | 0.312 |
| Sr-mmp | 0.936 |
| Sr-p53 | 0.547 |
| Vol | 394.48 |
| Dense | 0.883 |
| Flex | 0.167 |
| Nstereo | 2 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 1 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 4 |
| Qed | 0.453 |
| Synth | 4.063 |
| Fsp3 | 0.5 |
| Mce-18 | 62.278 |
| Natural product-likeness | 2.234 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |